What to Do If Your Pharmacy Doesn't Accept Medicare Bridge

By Weight Loss Provider Guide · Last verified: August 5, 2026 · Resolver version 1.0

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We are not affiliated with Medicare, CMS, Humana, any pharmacy chain, or any drug maker.

Start here: your pharmacy's first answer may not be the final answer

Here's what to do if your pharmacy doesn't accept Medicare Bridge: stop, ask for the pharmacist, and get the exact reject code plus the full message. CMS says pharmacies do not need to opt in before processing Medicare GLP-1 Bridge claims. But that does not force every pharmacy to stock or dispense every covered drug, and CMS's own reject guide includes code 930 for a pharmacy that is precluded from the program. A spoken “we don't take that” does not tell you which situation you are in.

The claim could be going to the wrong payer. It could need prior authorization. Your Medicare Number or demographic record could be mismatched. The product, package, quantity, refill date, prescriber, pharmacy, or eligibility record could be the problem. Or the store may simply have no stock and no plan to order it.

But there's a catch nobody tells you at the counter: the words a pharmacy employee says out loud often do not match the exact reason the claim failed. “Not covered” can describe several completely different problems, each owned by a different person. Until you get the real code and full message, you're guessing.

If you are eligible, the exact product is covered, and the prior authorization is approved, the Bridge copay is $50 for one 28- or 30-day fill. Do not pay cash expecting Medicare Bridge to reimburse you later. CMS accepts electronic pharmacy claims only; no paper claim or direct member-reimbursement path exists. (CMS pharmacy guidance)

That's what the rest of this page fixes.

Four things change the answer. First, you must be in an eligible Part D plan type and meet the Bridge's clinical criteria for weight-management use. Second, a code 65 message may show a real eligibility stop—such as an ineligible plan type, no Part D enrollment on the fill date, or a prior 2026 GLP-1 fill through Part D—or it may show a record problem that can be corrected. Third, the drug and exact formulation must be on the current list: Foundayo, Wegovy injection or tablets, or Zepbound KwikPen. Zepbound vials and single-dose pens are not covered. Fourth, a store can be operationally unready, out of stock, unwilling to order, or precluded even though no advance pharmacy enrollment is required. (CMS pharmacy guidance) (CMS reject-code tool)

Is this page for you?

The 60-second version

Open the free Pharmacy Action Card
One page you can print or show on your phone. It has the billing route, the pharmacy-only help-desk number, all current covered NDCs, and the exact questions to ask. No email, no sign-up, and no personal information.

Does your pharmacy have to accept the Medicare GLP-1 Bridge?

No advance pharmacy enrollment is required, but that is not the same as a rule forcing every store to stock or dispense the drug. CMS says pharmacies do not need to opt in to participate and charges no transaction or click fee for Bridge claims. A location can still lack the exact product, decline to order it, be unable or unwilling to complete the workflow, or return code 930 because the pharmacy is precluded. (CMS pharmacy guidance) (CMS reject-code tool)

Let's slow down on that, because it is the whole page.

Normal Medicare drug coverage has networks. Your plan signs contracts with pharmacies. Some pharmacies are preferred, some are not, and where you fill can change your Part D cost.

The Bridge does not run through that ordinary Part D payment flow. It is a Section 402 demonstration operating nationwide through a single central processor from July 1, 2026, through December 31, 2027. CMS gives pharmacies a dedicated billing route and says they do not need to opt in before using it. (CMS pharmacy guidance)

That gives you a much better question than “Are you a participating pharmacy?”

Ask this instead:

“Can the pharmacist submit a Medicare GLP-1 Bridge claim using BIN 028918 and PCN MEDDGLP1BR, and do you have my exact covered product in stock?”

That question separates permission from readiness. Permission is not the usual problem. Readiness, stock, product match, claim data, prior authorization, and pharmacy status are.

So why do people think there is a pharmacy network?

Because “participating pharmacy” is still being used as consumer shorthand. We checked the current language against CMS's operational rule:

“A participating pharmacy” is easy shorthand. It becomes harmful when a beneficiary hears it as “there is a secret network and I picked the wrong store.” CMS does not publish an enrollment-based directory because pharmacies do not enroll in advance.

It was not your fault that the words sounded like a closed network. There is no list you failed to join.

One honest line before we move on: no opt-in required does not mean every pharmacy will do it today. A pharmacy can be able to submit the route and still have no drug in the building, no trained staff on that shift, no willingness to order an expensive product, or a preclusion edit that cannot be fixed at that location. Those are different problems with different next moves.

Why “we don't take that” is not enough to identify the problem

A spoken refusal at a pharmacy counter is a summary, not the claim diagnosis. When the Bridge adjudicates a rejected claim, the pharmacy receives an NCPDP reject code and, for many edits, a fuller message. The code and message determine whether the next action belongs to the pharmacy, your prescriber, Medicare or Social Security, the timing of the fill, or a different pharmacy. (CMS reject-code tool)

This is the single most important habit on this page. Get the code.

Not “what's wrong?” Not “can you try again?” Ask for the NCPDP reject code and the complete message that came back with it.

Write down:

• The code
• The full message
• Which payer received the claim
• The date and time
• The pharmacy location
• Whether a prior-authorization request was sent
• Whether the pharmacist called the Bridge Pharmacy Help Desk

Once you have that, the rest of this page becomes a lookup instead of an argument.

What the pharmacy's words may actually mean

Every row above is tied to CMS's current pharmacy guidance or its June 2026 reject-code tool. The table does not pretend to diagnose a claim from a spoken sentence. It shows what fact you need next.

Medicare Bridge Pharmacy Refusal Resolver — version 1.0

CMS's June 2026 reference contains 40 reason rows across 30 distinct reject-code values. We regrouped those 40 rows into nine patient-facing action buckets so you can see who owns the next move without reproducing NCPDP's copyrighted descriptions.

The code count is not a probability table. Thirty code values do not mean every code occurs equally often. The value of this dataset is simpler: it stops you from treating every rejection as the same problem.

Get your counter script for what they actually told you
Pick the sentence you heard. The resolver should return the likely branches, the missing fact, who owns the next step, the exact words to use, and whether to retry, wait, correct, escalate, or transfer. It should never ask for your Medicare Number, Social Security number, name, date of birth, diagnosis, or prescription number.

What to Do If Your Pharmacy Doesn't Accept Medicare Bridge: Ask These Four Questions

Four questions, asked in order, turn a vague refusal into a specific next action. They tell you where the claim went, what came back, whether the prior-authorization handoff happened, and whether the pharmacy has the exact covered product. Ask for the pharmacist rather than relying on a register-level summary, because the pharmacist can inspect the claim response and use the pharmacy-only support line. (CMS pharmacy guidance)

Read these out loud. Seriously. Print them if you want to.

Question 1 — Where did the claim go?

“Could you check whether this went to my Part D plan or to the Medicare GLP-1 Bridge? The Bridge route is BIN 028918, PCN MEDDGLP1BR, using my current Medicare Number.”

BIN and PCN are the routing fields that tell a pharmacy system where to send the claim. The Bridge has its own route, and it is separate from your ordinary Part D claim flow.

Question 2 — What exactly came back?

“What is the exact NCPDP reject code and the complete message?”

Write it down. Time, date, code, message, store name. This becomes your case file, and it makes every later call shorter and more useful.

Question 3 — Is there a prior authorization, and where is it?

“Is a prior authorization required? If it is, did you send the request to my prescriber? Was it sent electronically or by fax, and when?”

Do not settle for “the doctor has it.” Ask when and how it was sent.

Question 4 — Do you have it, and is it the right version?

“Do you have the exact prescribed product, strength, device, and NDC in stock? If this is Zepbound, is it the KwikPen specifically?”

“Zepbound is in stock” is not enough. The Bridge excludes the Zepbound vial and single-dose pen.

Five answers you should not accept without one more fact

Waiting can be correct. Code 85 may need a retry. Code 79 has a payable refill date. A prior authorization needs time after submission. A pharmacy may be waiting for stock. But “try later” without the code or the event that will change is not a plan.

Open the Counter Script Builder
Choose the sentence you heard and get the next script without entering personal information.

Did the claim even go to the right place?

The Medicare GLP-1 Bridge uses its own billing route—BIN 028918 and PCN MEDDGLP1BR—and operates outside the ordinary Part D payment flow. A Part D denial is not required before a pharmacy submits a potentially eligible weight-management claim directly to the Bridge. But if the drug is prescribed for a use Part D can cover, Part D may be the correct route instead. (CMS pharmacy guidance) (CMS Part D guidance)

Here's why the destination matters.

Federal law generally excludes drugs when used for weight loss from ordinary Part D coverage. That is the gap the temporary Bridge is testing. If a pharmacy sends a prescription used solely for weight management through the ordinary Part D route, the plan may reject it because that use is excluded.

But do not turn that into “all GLP-1 Part D claims are wrong.” CMS says type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis—MASH—are Part D-coverable indications. A prescription intended to reduce major adverse cardiovascular-event risk also belongs in the Part D route. The prescribed use controls the route. (CMS provider guidance)

Your insurance may have denied the claim. The more useful question is whether your insurance was supposed to be asked.

Things to know about the Bridge route

• It is the primary payer for products furnished under the Bridge and does not coordinate benefits with another payer.
• Coupons and discount cards cannot be applied to a Bridge claim.
• No paper claims and no direct member reimbursement. The central processor accepts electronic NCPDP pharmacy claims.
• The pharmacy needs your MBI—your Medicare Beneficiary Identifier, also called your Medicare Number.
• If you do not have the card, CMS says a pharmacy may ask for the last four digits of your Social Security number to perform an E1 lookup for your Medicare Number. Use that route only with the pharmacy or another legitimate Medicare channel. Do not enter it into this website, email it to us, or post it publicly. (CMS pharmacy guidance)

The diagnosis code nobody mentions

This is the piece that matters in the real workflow.

CMS says a diagnosis code and a note directing the pharmacy to the Bridge are recommended but not required for a Bridge claim to process. They help route the prescription appropriately. (CMS provider guidance)

Now the counter reality. A community pharmacist may not have access to the prescriber's full chart. A clear diagnosis code and a note such as “Medicare GLP-1 Bridge—weight-management use” can remove ambiguity about whether the prescription belongs with Part D or the Bridge. Pharmacy trade reporting has identified that routing friction as a practical implementation problem. (Drug Topics interview)

So CMS calls the field optional. The pharmacy workflow may still benefit from it.

What to do with that: if the claim keeps going to the wrong payer or the pharmacy cannot tell which route applies, ask the prescriber's office to resend or clarify the prescription with the accurate weight-management diagnosis code and a Bridge routing annotation. That is not a guarantee of approval. It is a clean way to remove one preventable routing problem.

That's a high-value five-minute call.

Is reject code 75 a denial?

No. Code 75 means prior authorization is required; it is not the final clinical approval or denial. For a first Bridge fill that clears the preliminary identity, eligibility, and product edits, code 75 is the expected handoff from the pharmacy to the prescriber. The next question is whether the request actually reached the prescriber and whether a complete form was submitted. (CMS reject-code tool) (CMS provider guidance)

Read that again if the word “rejected” scared you. The first claim can reject because the program needs the prior authorization before it will pay.

Who actually decides

Not your pharmacy. Not your Part D plan.

CMS uses Humana as the central processor for Bridge prior authorization, claims adjudication, and pharmacy payment. Your pharmacy can submit the claim and transmit the PA request, but it does not make the clinical coverage decision. (CMS pharmacy guidance)

A beneficiary described this exact confusion in a public Medicare Rights Center comment: her doctor had completed the form, but she was still “waiting for pharmacy to approve it.” That comment is voice-of-customer evidence, not proof of how any individual claim was handled. The useful lesson is that the pharmacy is a handoff point, not the clinical decision-maker. (Medicare Rights Center comments)

The real timeline

The two 72-hour windows are not the same thing. The first is the typical pharmacy-to-prescriber transmission window. The second begins after the prescriber submits the prior authorization.

The escape hatch almost nobody knows about

If 72 hours pass and the prescriber has not received the pharmacy's electronic or fax request, CMS says the prescriber can download the Bridge fax form from the CMS provider page and submit it directly. (CMS provider guidance)

That does not erase the pharmacy from every later step—the pharmacy still has to dispense and process the approved claim—but it stops the prescriber's office from waiting indefinitely for a form that never arrived.

Tell the office that sentence. It is one of the cleanest unlocks on this page.

Once the PA is approved

A Bridge prior authorization remains valid through December 31, 2027. CMS says refills and dose changes on the same covered drug do not require a new PA. Switching from one covered GLP-1 drug to another does. (CMS pharmacy guidance)

If your doctor's office has gone quiet

That is a different problem from a pharmacy rejection. Start with the Medicare Bridge paperwork guide or the Bridge prior-authorization provider guide.

CMS says a prescriber does not have to be enrolled in Medicare to write the prescription or submit the Bridge PA, but the prescriber must not be on Medicare's Preclusion List. The real question is whether a licensed, appropriate prescriber is willing and prepared to submit the CMS form. (CMS provider guidance)

Do not buy a telehealth membership merely because a page promises generic “prior-authorization support.” We verified that Sesame's public weight-loss program starts as low as $59 per month with an annual commitment, medication is separate, and Sesame says its providers handle insurance PA paperwork. We could not verify a public promise that every Sesame clinician will file the separate CMS Medicare GLP-1 Bridge form. Confirm that specific service before paying. (Sesame program)

Find a provider path that can actually handle Bridge paperwork
Use this when your own office will not submit the form—not while a pharmacy request is simply still inside the published transmission window.

Does the pharmacy have the exact drug in stock?

An out-of-stock answer is an inventory problem, not proof that the Bridge denied you. GLP-1 products are expensive and may not be routinely stocked. A pharmacist quoted by Pharmacy Times said pharmacies can sometimes have them ready the business day after prior authorization, but that is an operational example—not a nationwide guarantee. Confirm the exact product, NDC, order status, and receiving-store stock. (Pharmacy Times)

That's the sentence we'd most like you to remember.

Not routinely stocked does not mean not covered.

Now let's take your pharmacist's side for a minute

Because it will change how you talk to them, and it may change what you do next.

CMS says the Bridge reimburses the pharmacy at the drug's wholesale acquisition cost, minus your $50 copay, plus a $3 dispensing fee—$5 for a beneficiary residing in long-term care—plus applicable sales tax. CMS also says it charges pharmacies no transaction or click fee. (CMS pharmacy guidance)

Wholesale acquisition cost is not necessarily the pharmacy's actual invoice cost. It is the manufacturer's published list price to wholesalers or direct purchasers before prompt-pay discounts, rebates, or other price reductions. (42 U.S.C. § 1395w-3a)

What CMS pays versus what the pharmacy has to carry

Here is the honest downside of this program, and we're not going to dress it up: CMS does not require a pharmacy to keep these products on the shelf, and the published dispensing fee is only $3 for most fills. A small pharmacy can look at the refrigeration, cash-flow, spoilage, and ordering burden and decide not to stock a particular product. You will not argue a box into the refrigerator.

But here's the part that flips it. The Bridge uses one central processor, pays on a WAC-based formula, and charges no claim transaction fee. Bryan Wheeler, PharmD, described that structure as giving independent pharmacies more predictability than many commercial GLP-1 claims, where pharmacy-benefit arrangements can produce negative margins. That is one pharmacist's operational assessment—not a CMS profit guarantee—but it explains why another pharmacy may be happy to fill the exact same prescription. (Drug Topics interview)

The reframe matters: stocking and claim coverage are two separate questions.

• If the claim has an identity, eligibility, PA, product, quantity, prescriber, or timing edit, changing pharmacies may reproduce the same problem.
• If the current store has no stock, will not order, refuses after the pharmacist checks the route, or returns code 930, another pharmacy may be the fastest answer.

If 90-day fills are what you need, the Bridge is not built for that. CMS limits Bridge dispensing to one 28- or 30-day supply at a time. If approved, the copay is the same flat $50 for the covered monthly fill. (CMS pharmacy guidance)

What about shortages?

FDA determined the semaglutide injection shortage was resolved on February 21, 2025. FDA removed tirzepatide injection from the shortage list on October 2, 2024, then reevaluated and confirmed the shortage was resolved on December 19, 2024. A resolved national shortage does not mean every product, dose, device, or local wholesaler has uninterrupted inventory every day. (FDA semaglutide update) (FDA tirzepatide decision)

Foundayo was FDA-approved on April 1, 2026. Its recent approval may still create local familiarity or ordering friction, but the page should not claim a national shortage or a universal rollout problem without current FDA or manufacturer evidence. (FDA Foundayo approval)

You are not the only person hearing this

Public comments from the first weeks of the program show the same implementation confusion in ordinary language:

“So far, CVS has NO CLUE how to process BRIDGE requests.”
— r/medicare, July 2026

A retail pharmacist separately posted a question asking whether Bridge billing had anything to do with Medicare Part B. It does not; the Medicare Number is being used as the beneficiary identifier for this separate claims route. (r/medicare thread) (r/pharmacy thread)

These are individual reports, not proof that CVS, any other chain, or any specific store always gets it wrong. But if you felt singled out at that counter, you weren't.

What if the pharmacy has Zepbound but not the KwikPen?

The Medicare GLP-1 Bridge covers Zepbound KwikPen only. CMS excludes Zepbound single-dose vials and single-dose pens and publishes six KwikPen NDCs that the pharmacy can match against the prescription and the package. A store can truthfully say “we have Zepbound” and still have no Zepbound product the Bridge will pay for. (CMS pharmacy guidance)

This one traps everybody.

An NDC is the National Drug Code for one exact product and package. The drug name alone is not enough. Same brand, different device, different NDC, different Bridge result.

Current Medicare GLP-1 Bridge product and NDC table

Verified against CMS on August 5, 2026. CMS says this list may change during the demonstration.

This table assembles all 22 currently listed NDCs in one place. Check the official CMS product list again if the page's verification date is old.

What code 70 means here

Code 70 means the submitted NDC is not eligible under the current Bridge list. It does not mean a different device with the same brand name will work. The pharmacist should compare the exact NDC; if the prescription is for a noncovered presentation, the prescriber must write for an eligible product when clinically appropriate. (CMS reject-code tool)

Two ways out

1. Ask whether the pharmacy can order the exact KwikPen NDC. Do not accept “we have Zepbound” without the device and NDC.
2. Discuss another covered drug with your prescriber. That requires a new prescription and a new Bridge PA because CMS says switching from one covered GLP-1 drug to a different covered GLP-1 drug restarts prior authorization.

Do not promise an ordering time. Wholesaler availability and store ordering schedules vary.

One thing to know, stated openly: CMS clearly says a new PA is required when the patient switches to a different covered GLP-1 drug and that dose changes on the same covered drug do not require one. CMS's public wording does not expressly answer every same-brand formulation change—for example, Wegovy injection to Wegovy tablet. Have the prescriber's office call the Bridge prescriber line at 855-273-0102 before changing formulations if the existing authorization status is unclear. (CMS provider guidance)

And do not let anyone swap your medication simply because a different product is in stock. A drug or formulation change is a clinical decision. It belongs to your prescriber, not to a shelf.

Can you switch pharmacies without starting over?

CMS explicitly names a switch from one covered GLP-1 drug to another as a reason for a new prior authorization; it does not tie the approval to one named pharmacy in its public guidance. That supports—but does not conclusively prove for every live claim—that a pharmacy-only transfer should preserve the existing PA. Confirm the authorization status, the exact product, and the receiving store's stock before moving anything. (CMS pharmacy guidance)

We want to be careful with this one, because it is the fear that keeps people arguing at a counter they should have already left.

Here's what is solid: approval runs through December 31, 2027. Refills and dose changes on the same covered drug do not require a new PA. Switching covered drugs does.

Here's what we will not overstate: CMS has not published a sentence saying, “Changing pharmacies never requires a new prior authorization.” So do not treat our reading as access to your live case. Ask the current pharmacist to verify the authorization and, if needed, call the pharmacy-only Bridge Help Desk. You can call 1-800-MEDICARE for beneficiary assistance.

Stay, retry, correct, or move?

Pharmacy transfer checklist

Before you call the new pharmacy, have:

• Exact drug name
• Strength
• Device or formulation—KwikPen, injection pen, or tablet
• Exact NDC
• Confirmation the receiving store has that exact product right now
• Confirmation the pharmacist can submit BIN 028918 / PCN MEDDGLP1BR
• Your current PA status
• The exact last reject code and message
• Whether the old store can transfer the prescription or the prescriber must send a new one
• Names, dates, and times from both calls

Prescription-transfer mechanics vary by state, pharmacy system, prescription status, and store policy. Ask the two pharmacies rather than assuming the transfer will be automatic.

Two fill rules worth knowing

• 28 or 30 days only. No 60-day fill, no 90-day fill, and no partial transition fill.
• Vacation fill: CMS provides a pharmacy point-of-sale vacation override using submission clarification code 003. There is no manual override and no override for lost or stolen medication. Plan ahead. (CMS pharmacy guidance)

On mail order: the public CMS pharmacy FAQ reviewed on August 5, 2026 limits days supply but does not give a simple consumer answer about every mail-order arrangement. Do not assume it works or does not work. Ask the receiving mail-order pharmacy whether it can submit the Bridge route and confirm with 1-800-MEDICARE before transferring.

Open the pharmacy transfer checklist
Confirm stock and processing before you move the prescription. That one call prevents the worst version of a transfer: arriving at a second pharmacy with the same problem and less time.

Which pharmacies accept Medicare Bridge?

CMS does not provide an enrollment-based “participating pharmacy” directory because pharmacies do not need to opt in before processing Bridge claims. What changes store by store is readiness: whether the pharmacist can submit the route, whether the exact product is in stock, whether staff can resolve the response, and whether the pharmacy has a preclusion edit. The reliable way to find a fill today is to verify the specific location. (CMS pharmacy guidance)

We're deliberately not publishing a chain-by-chain “accepted here” list, and we want to tell you why—because a neat list could send you to the wrong parking lot.

A statement like “CVS accepts Medicare Bridge” falls apart four different ways:

1. Inventory is per store. One location may have the exact KwikPen; another may have only a noncovered Zepbound presentation.
2. Staff experience is per shift. One pharmacist may have processed Bridge claims; another may need the payer sheet and help desk.
3. A particular billing pharmacy can return a preclusion edit. Code 930 is a pharmacy-level hard stop.
4. Corporate readiness does not predict today's fill. The store can know the program and still have no product.

So a chain directory would make us look authoritative and leave you standing at the wrong counter. No thanks.

Call ahead instead. Here's the script.

“Can your pharmacist submit a Medicare GLP-1 Bridge claim using BIN 028918 and PCN MEDDGLP1BR? Do you have [exact drug, strength, device, and NDC] in stock now? If the claim rejects, will the pharmacist provide the complete reject code and message or call the Bridge Pharmacy Help Desk?”

Three clear yeses and you're driving over. One unclear answer and you have saved yourself a trip.

Independent pharmacies are worth calling. A June 2026 Drug Topics interview framed the Bridge as an opportunity for independent pharmacies to compete on service, while also describing the inventory and workflow burden. That is not a promise that every independent pharmacy will stock the drug. It is a reason not to limit your search to the biggest chain. (Drug Topics interview)

Who should you call about a Medicare Bridge pharmacy problem?

Different support lines serve different people. The pharmacist calls the Bridge Pharmacy Help Desk for claim submission and claim status. The prescriber's office calls the prescriber support line for PA questions and status. Beneficiaries call 1-800-MEDICARE or SHIP for personal program help. Calling a professional-only line yourself may not get your case resolved. (CMS pharmacy guidance) (CMS provider guidance)

Who can see what

This matters, and it saves wasted calls:

• Your pharmacy can see the point-of-sale claim response and reject message.
• Your prescriber can see the PA request it received and the submission it sent.
• The central processor adjudicates the Bridge PA and claim.
• Medicare can help a beneficiary understand program rules and next steps.
• We cannot see any of it. We can tell you what the published rules say. We cannot open your claim, determine your eligibility, or check a store's live inventory.

Before anyone calls, have this ready

Exact reject code. Full message. Date and time. Store name and location. Which payer received the claim. Whether a PA was sent. Your drug, strength, device, and NDC.

Do not enter your Medicare Number, Social Security number, date of birth, prescription number, diagnosis, or denial letter into the tools on this page.

Save the call order: pharmacy problem → pharmacist; PA problem → prescriber; personal Medicare question → 1-800-MEDICARE.

When is it a real denial and not a pharmacy problem?

Three different events get called “denied,” and they have three different fixes. A pharmacy rejection happens at the point of sale before the Bridge has necessarily evaluated the clinical criteria. A Bridge PA denial happens after the prescriber submits the form. A Part D denial happens under the beneficiary's drug plan and carries the ordinary Part D coverage-determination and appeal rules. (CMS provider guidance) (CMS Part D guidance)

The part other pages can get wrong in opposite directions

Let's be precise, because a wrong appeal path can cost weeks.

There is no formal appeals process under the Medicare GLP-1 Bridge. CMS says a prescriber may resubmit if the original form contained incorrect information or if the prescriber has updated or additional information. That is not an unlimited right to keep sending the same unchanged request. (CMS provider guidance)

But ordinary Part D appeal rights are unchanged. CMS tells Part D plans that the Bridge does not alter beneficiary coverage-determination, exception, or appeal rights for Part D coverage. If the drug is prescribed for a Part D-coverable use, the plan must handle that request through the normal Part D process. (CMS Part D guidance)

Both things are true at once. The Bridge has no formal appeal. Part D still does.

The practical difference:

• If the Bridge PA was denied because the form was wrong, incomplete, outdated, or missing relevant information, the prescriber can correct it and resubmit.
• If the Bridge criteria genuinely are not met, repeating the same form does not create eligibility.
• If Part D should cover the prescribed use, pursue the plan's coverage and appeal route rather than trying to force the claim into the Bridge.

Most people do not need a made-up appeal route. They need the correct reason, the correct payer, and a form that accurately documents the criteria.

What if you are actually not eligible?

Before you blame the pharmacy, confirm the four eligibility gates and the common hard stops. The Bridge is not universal Medicare coverage for every GLP-1 or every beneficiary. If the plan type, prescribed use, clinical criteria, prior-coverage record, product, or PA decision fails, rebilling the same claim will not solve it. (Medicare beneficiary fact sheet)

Gate 1: You have an eligible Part D plan type

Eligible 2026 plan types include:

• Standalone Medicare Part D prescription drug plans
• Medicare Advantage coordinated-care plans with drug coverage: HMO, HMOPOS, local PPO, and regional PPO
• Special Needs Plans
• Employer or union group waiver plans
• LI NET

CMS says private fee-for-service plans, Section 1876 cost plans, Section 1833 health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans are not eligible unless the beneficiary is also enrolled in a standalone PDP where applicable. Dually eligible beneficiaries can use the Bridge when they have an eligible Part D plan type and meet the PA criteria. (CMS pharmacy guidance)

Gate 2: The prescription is for Bridge-covered weight-management use

The drug must be prescribed to reduce excess body weight and maintain weight reduction with ongoing structured nutrition and physical activity consistent with the FDA-approved label.

CMS routes prescriptions for these uses through Part D instead:

• Type 2 diabetes
• Moderate-to-severe obstructive sleep apnea
• Noncirrhotic MASH
• Reduction of major adverse cardiovascular-event risk when that is a prescribed use

That does not mean the condition or the medicine is unimportant. It means the claim belongs in a different Medicare lane. (CMS provider guidance)

Gate 3: You meet one of the clinical paths at GLP-1 therapy initiation

The prescriber must attest that the beneficiary was at least 18 and met one of these paths when GLP-1 therapy began:

1. BMI 35 or higher, or
2. BMI 30 or higher with at least one of these:
   • Heart failure with preserved ejection fraction
   • Uncontrolled hypertension—above 140 systolic or 90 diastolic despite treatment with two antihypertensive medications
   • Chronic kidney disease stage 3a or higher
3. BMI 27 or higher with at least one of these:
   • Prediabetes
   • Prior myocardial infarction
   • Prior stroke
   • Symptomatic peripheral artery disease

CMS says the criteria are measured at the time of GLP-1 therapy initiation, including therapy started before Medicare Part D enrollment or before the Bridge began. (CMS provider guidance)

Gate 4: You have a covered product and an approved prior authorization

The current product list is:

• Foundayo—all current CMS-listed formulations
• Wegovy—injection and tablets
• Zepbound—KwikPen only

Ozempic, Mounjaro, Zepbound vials, and Zepbound single-dose pens are not on the current Bridge product list. (CMS pharmacy guidance)

Common code 65 hard stops and record problems

Code 65 alone is not a diagnosis. CMS's current tool uses it for six different messages:

Some of these are genuine eligibility stops. Some can be wrong records. That is why the complete message matters.

A few rules that surprise people

• The $50 does not count toward the Part D deductible or TrOOP.
• The Bridge provides no low-income subsidy; eligible beneficiaries pay the same $50.
• Bridge drugs are not eligible for the Medicare Prescription Payment Plan.
• Pen needles for Zepbound KwikPen are not covered through the Bridge or Part D for this Bridge fill; CMS says patients can purchase them separately.
• Coupons and discount cards cannot be stacked onto the Bridge claim. (CMS pharmacy guidance) (Medicare beneficiary fact sheet)

If one of the real eligibility stops applies, stop trying to fix a pharmacy-only problem. Move to the correct Part D, prescriber, or cash-pay path.

What if the Bridge genuinely will not work for you?

Only use the cash-pay section after you have separated a correctable pharmacy problem from true ineligibility or a final Bridge PA problem. An approved Bridge fill at $50 is cheaper than every current manufacturer and telehealth cash route below. But FDA-approved self-pay options now start at $149 per month, not $299–$349 across the board. (NovoCare Wegovy pricing) (Foundayo pricing)

If you are still working a fixable code, close this section and go make the call. $50 beats everything below by a mile.

You have two real routes.

Route 1: Use a manufacturer cash-pay program with your existing prescription

Manufacturer pharmacy programs can be the lowest-cost route when you already have a valid prescription and do not need a new telehealth membership. They are cash programs, not Bridge claims, and the purchase does not count toward your Medicare deductible or out-of-pocket limit.

Current manufacturer cash prices verified August 5, 2026

These programs require a valid on-label prescription. They do not replace the clinical evaluation or the prescriber who must issue it. (NovoCare terms) (LillyDirect Zepbound) (Foundayo pricing)

Route 2: Use telehealth for the prescriber plus the cash-pay medication path

For a Medicare beneficiary who has exhausted the Bridge and wants FDA-approved brand medication plus ongoing telehealth care, Ro is the stronger broad cash-pay route in this page's comparison. Ro's public page lists a $39 first month, $149 ongoing monthly membership, or as low as $74 per month with an annual plan paid upfront. Medication is separate. Ro says Medicare, Medicare Supplement, and TRICARE beneficiaries may be eligible for certain cash-pay options. (Ro pricing) (Ro government-insurance policy)

Sesame is the better fit when choosing an individual clinician matters more than one standardized membership. Its Success by Sesame program starts as low as $59 per month with a 12-month commitment; month-to-month is listed at $99, and medication is separate. (Sesame program)

Provider-stated versus independently verified

One hard line: Ro is not the tool for getting the $50 Bridge paperwork filed. Its public government-insurance policy does not promise ordinary Medicare coordination, and its free checker does not check Foundayo, Wegovy pill, or Zepbound KwikPen. Use Ro after the Bridge is genuinely unavailable, not as a substitute for a correctable Bridge claim. (Ro government-insurance policy) (Ro insurance checker)

And a straight answer on compounded GLP-1s, since you will see ads for them: we're not recommending them on this Medicare Bridge page. Compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before marketing. They are not the FDA-approved Bridge products and cannot be described as generic or the same as the approved brands. (FDA compounding Q&A)

See verified Medicare Bridge alternatives
Use this after you know the Bridge will not work—not while the pharmacy is still holding a correctable claim.

See current FDA-approved cash-pay paths
Check the membership fee, medication price, commitment, cancellation terms, and whether you already have a prescriber before you pay.

What we actually verified

We think you should be able to check us. This box separates official program facts from conclusions the page cannot make about your individual claim.

Verified at the source on August 5, 2026

• CMS says pharmacies do not need to opt in to the Medicare GLP-1 Bridge.
• The program runs nationwide from July 1, 2026, through December 31, 2027.
• The Bridge operates outside the ordinary Part D payment and coverage flow through one central processor, Humana.
• The billing route is BIN 028918 and PCN MEDDGLP1BR.
• A prior Part D denial is not required before a potentially eligible claim is sent directly to the Bridge.
• A diagnosis code and Bridge annotation are recommended for routing but not required for claim processing.
• Current covered products are Foundayo, Wegovy injection and tablets, and Zepbound KwikPen; the current CMS list contains 22 NDCs.
• Zepbound single-dose vials and single-dose pens are excluded.
• Approved fills are one 28- or 30-day supply; 60-day, 90-day, and partial transition fills are not available.
• Vacation override code 003 is available at the pharmacy point of sale; there is no manual override and no lost-or-stolen override.
• PA approval is valid through December 31, 2027; no new PA is required for refills or dose changes on the same covered drug; a drug switch requires a new PA.
• CMS's June 2026 pharmacy tool contains 40 reason rows across 30 distinct reject-code values; we regrouped them into nine action buckets.
• The pharmacy-to-prescriber PA request typically takes 24–72 hours; the decision is sent within 72 hours after submission.
• If the prescriber receives no request after 72 hours, the prescriber can download and submit the fax form directly.
• The Bridge has no formal appeals process; a prescriber may resubmit with corrected, updated, or additional information.
• Part D coverage-determination and appeal rights remain unchanged.
• The Bridge is the primary payer, does not coordinate benefits, does not accept coupons or discount cards, and provides no paper claim or direct member reimbursement.
• The approved beneficiary copay is $50, does not count toward the Part D deductible or TrOOP, and receives no low-income subsidy.
• Bridge drugs are not eligible for the Medicare Prescription Payment Plan.
• Pen needles for Zepbound KwikPen are not covered by the Bridge.
• Pharmacy reimbursement uses WAC minus the $50 copay, plus a $3 dispensing fee—$5 in long-term care—and applicable sales tax.
• CMS charges pharmacies no transaction or click fee for Bridge claims.
• Current phone numbers and role boundaries: pharmacy help desk 844-673-0910; prescriber support 855-273-0102; beneficiary help 1-800-MEDICARE; NovoCare Obesity & Bridge Support 888-809-3942.
• FDA's national shortage determinations for semaglutide injection and tirzepatide injection remain resolved as described above.
• Current manufacturer cash prices and the material offer conditions listed in the cash-pay table.
• Current Ro and Sesame public program pricing, medication-exclusion language, and the Ro cancellation facts listed in the provider table.

What we could not confirm—and are telling you instead of guessing

• Whether every approved PA will transfer between pharmacies without any case-specific issue. CMS names a drug switch as the trigger for a new PA and does not tie approval to a named pharmacy, but the public guidance does not state that every pharmacy-only transfer is automatic.
• Whether every mail-order pharmacy can process the Bridge. The public CMS pharmacy FAQ reviewed does not provide one universal answer.
• Whether every same-brand formulation change counts as remaining on the same “covered drug.” CMS clearly addresses dose changes and switches between covered GLP-1 drugs but does not answer every device or dosage-form scenario in one sentence.
• Which individual retail locations have a covered product in stock today.
• Whether any individual Sesame clinician will submit the Medicare Bridge PA. Sesame's public page promises general insurance PA support; it does not establish a Bridge-specific promise for every clinician.
• Whether a specific pharmacy employee, prescriber, or central-processor reviewer will resolve your case on a particular day.

Also worth saying plainly: we cannot see your claim, determine your eligibility, or tell you whether a store has your medication today. Any website claiming otherwise without access to the official systems is guessing.

How we built this page

We built this page from official Bridge rules first, then used pharmacy-profession reporting and public comments only to understand implementation friction and the words people hear. CMS and Medicare control every program, eligibility, payment, product, code, timing, and appeal conclusion on this page.

We reviewed:

• The CMS Medicare GLP-1 Bridge overview
• The separate CMS pharmacy and provider FAQs
• Medicare's beneficiary fact sheet
• The CMS June 2026 pharmacy reject-code reference tool
• CMS's Part D plan expectations and FAQ
• Current FDA approval, shortage, and compounding sources
• Current manufacturer pricing and offer terms
• Current Ro and Sesame public pricing and policy pages

Then we did something we had not seen in one consumer resource: we counted the official tool's 40 reason rows and 30 distinct code values, regrouped them into nine action buckets, and mapped ordinary counter language to the fact a beneficiary needs next.

We also read pharmacist trade reporting because official billing instructions do not tell a frightened person why a store may hesitate to order an expensive refrigerated product for a $3 dispensing fee. Named pharmacists supplied operational context; CMS still controls the rule.

We used public forum and comment threads for one purpose only: to learn the actual words people report hearing at the counter. Not for medical, safety, eligibility, or coverage claims.

Method for the refusal resolver

For each pharmacy statement, we:

1. Listed every official claim branch that could produce that statement.
2. Refused to pick one branch when the exact code and full message were still missing.
3. Mapped each code to the party who owns the next action.
4. Wrote a plain-language counter script.
5. Assigned the next move: correct, retry, wait, escalate, or transfer.
6. Marked every medication or formulation change as a prescriber decision.
7. Attached the official source and verification date.

Resolver limitations

• A spoken pharmacy message can summarize several different claim responses.
• The tool cannot see the live claim.
• It cannot determine personal eligibility.
• It cannot guarantee approval or inventory.
• It cannot replace the pharmacist, prescriber, central processor, Medicare, or SSA.
• Covered products, prices, codes, support details, and policies can change.

Version history

Nobody paid us to write this. We may earn commission from some commercial services linked after the Bridge troubleshooting and eligibility sections. That compensation did not change the government-program instructions, the reject-code mapping, or the order of the options. You will notice we spent most of this page trying to get the eligible reader the $50 fill instead.

Frequently asked questions

These short answers cover the follow-ups most likely to send someone back to search. Use the linked sections above for the full decision path, and use the exact claim message—not a verbal summary—when the answer depends on your case.

Do pharmacies have to accept the Medicare GLP-1 Bridge?

CMS says pharmacies do not need to opt in before processing Bridge claims. That does not force every pharmacy to stock or dispense every covered product, and code 930 means a precluded pharmacy cannot process the claim. Ask whether the pharmacist can submit the route and whether the exact product is in stock.

Is there a list of participating Bridge pharmacies I can search?

CMS does not publish an enrollment-based directory because no advance pharmacy opt-in is required. Call the specific store and verify BIN 028918, PCN MEDDGLP1BR, the exact drug/device/NDC, current stock, and whether the pharmacist will inspect or escalate a rejection.

Why did my pharmacy bill my Part D plan instead?

The pharmacy may have followed its ordinary Medicare workflow or lacked a clear routing annotation. For weight-management use that may belong with the Bridge; for type 2 diabetes, moderate-to-severe obstructive sleep apnea, noncirrhotic MASH, or cardiovascular-risk-reduction use, Part D may be the correct route. Ask which payer received the claim and why.

Do I need a Part D denial first?

No. CMS says a Part D denial is not required before a potentially eligible claim is submitted directly to the Bridge.

Is reject code 75 a denial?

No. Code 75 means prior authorization is required. Confirm when and how the pharmacy sent the request to your prescriber, then confirm when the prescriber submitted the completed form.

Can I submit the Bridge prior authorization myself?

No. The pharmacy initiates the request after the claim returns code 75, and the prescriber submits the PA electronically or by fax. If the prescriber receives no request after 72 hours, CMS says the prescriber can download and submit the fax form directly.

How long does a Medicare Bridge prior authorization take?

CMS says the pharmacy typically transmits the PA request to the prescriber within 24–72 hours. The patient and prescriber should receive the approval or denial within 72 hours after the completed PA is submitted. Missing information, office delay, weekends, stock, and claim resubmission can extend the total time from first pharmacy visit to filled prescription.

Can my pharmacy charge me more than $50?

A beneficiary who is eligible, approved, and receiving a covered Bridge product pays a $50 copay for the 28- or 30-day fill. A higher quote usually means the claim did not process as an approved Bridge claim, the product is not covered, or the pharmacy is quoting a separate cash route. Get the code before paying.

Can I use a Wegovy or Zepbound savings card with the Bridge?

No. CMS says coupons and discount programs cannot be applied to Bridge claims.

Can I pay cash now and get reimbursed later?

No. The central processor accepts no paper claims and provides no direct member reimbursement. Do not pay full price expecting the Bridge to refund it.

Does switching pharmacies require a new prior authorization?

CMS expressly requires a new PA when the patient switches from one covered GLP-1 drug to another. It does not tie approval to a named pharmacy in its public guidance, but it also does not promise every pharmacy transfer will be automatic. Confirm the existing authorization and exact product before transferring.

Does changing my dose require a new prior authorization?

CMS says no new PA is required for dose changes when the patient remains on the same covered GLP-1 drug.

Does changing from Wegovy injection to Wegovy tablets require a new prior authorization?

CMS's public guidance does not expressly resolve every same-brand formulation change. Have the prescriber's office confirm with the Bridge prescriber line before changing the prescription.

Why was my Zepbound prescription rejected?

Check the device and NDC. The Bridge covers Zepbound KwikPen only. Zepbound vials and single-dose pens are excluded. Code 70 points toward an ineligible product or NDC.

Can I get a 90-day supply?

No. The Bridge covers one 28- or 30-day supply per fill. It does not provide 60-day, 90-day, or partial transition fills.

What happens if I need an early vacation fill?

The pharmacy can use point-of-sale submission clarification code 003 for a vacation override. CMS provides no manual override and no override for lost or stolen medication.

Does the $50 count toward my Part D out-of-pocket limit?

No. The Bridge operates outside Part D. The $50 does not count toward the Part D deductible or TrOOP and is not eligible for the Medicare Prescription Payment Plan.

Does Extra Help reduce the $50?

No. CMS says there is no low-income subsidy under the Bridge; eligible beneficiaries pay the same $50 copay.

Are Zepbound KwikPen needles covered?

No. CMS says pen needles are not covered by the Bridge and should not be billed to the Bridge or the patient's Part D plan for this fill. Patients can purchase them separately.

What if I miss a dose while this gets sorted out?

Call your pharmacist or prescriber and follow the official instructions for your exact medication. Dosing guidance differs by product and by how much time has passed, so this page will not give one generic missed-dose rule.

Does my prescriber have to be enrolled in Medicare?

No. CMS says the prescriber does not need Medicare enrollment to write the prescription or submit the Bridge PA, but the prescriber must not be on Medicare's Preclusion List.

Can I appeal a Bridge denial?

There is no formal Bridge appeal. The prescriber may resubmit if the original request was incorrect or if updated or additional information is available. Part D appeal rights remain available for a Part D coverage request.

When does the Medicare GLP-1 Bridge end?

The program is scheduled to run through December 31, 2027. CMS says the Bridge was extended after BALANCE did not launch in Part D in 2027, while CMS gathers data ahead of potential future implementation.

One thing to do next

You do not have to solve this whole thing today. You have to do one thing.

Get the code.

Call the pharmacy or walk back in, ask for the pharmacist, and ask for the exact reject code and the complete message. Write it down with the date, payer, and store name.

That's it. That's today's job.

Because once you have that code, you are not the person who got told no anymore. You are the person who knows what happened, who owns the next step, and what to say next. CMS's 30 current code values include many correctable identity, routing, PA, product, quantity, timing, format, and prescriber-data branches. Your job is not to guess which one you have.

Open the free Pharmacy Action Card
BIN and PCN, all 22 current covered NDCs, the correct phone-line roles, and the four questions. Print it or pull it up on your phone. No email, no account, and no personal information.

Medicare GLP-1 Bridge Pharmacy Action Card

Last verified: August 5, 2026 · Card version 1.0

Show this to the pharmacist

“Could you please check whether this prescription belongs with the Medicare GLP-1 Bridge rather than my Part D plan? The Bridge billing route is BIN 028918 and PCN MEDDGLP1BR, using my current Medicare Number. If the claim rejects, please tell me the exact NCPDP reject code and complete message. If pharmacy assistance is needed, the Bridge Pharmacy Help Desk for pharmacies is 844-673-0910.”

Four questions

1. Which payer received the claim—Part D or the Bridge?
2. What is the exact reject code and complete message?
3. Was a PA request sent to the prescriber, when, and by what method?
4. Is the exact covered product, device, strength, and NDC in stock?

Current covered NDCs

Foundayo: 0002-4178-31 · 0002-4503-31 · 0002-4794-31 · 0002-4803-31 · 0002-4839-31 · 0002-4953-31

Wegovy: 0169-4525-14 · 0169-4505-14 · 0169-4501-14 · 0169-4517-14 · 0169-4524-14 · 0169-4415-31 · 0169-4404-31 · 0169-4409-31 · 0169-4425-31 · 0169-4572-14

Zepbound KwikPen only: 0002-3511-11 · 0002-3522-11 · 0002-3533-11 · 0002-3544-11 · 0002-3555-11 · 0002-3566-11

Call the right line

• Pharmacy claim help—pharmacy calls: 844-673-0910
• PA help—prescriber's office calls: 855-273-0102, Monday–Friday, 8 a.m.–7 p.m. ET
• Beneficiary help—you call: 1-800-MEDICARE / 1-800-633-4227; TTY 1-877-486-2048
• Wegovy-specific NovoCare support: 888-809-3942, Monday–Friday, 8 a.m.–8 p.m. ET

Do not pay cash expecting reimbursement

The Bridge accepts electronic pharmacy claims only. It does not accept paper claims or reimburse members directly.

Privacy

Do not enter your Medicare Number, Social Security number, date of birth, prescription number, diagnosis, or denial letter into Weight Loss Provider Guide's tools.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

The quiz gives you an educational action plan. It does not determine Medicare eligibility and does not replace your prescriber, pharmacist, Medicare, or the central processor.

Sources

CMS and Medicare

• CMS — Medicare GLP-1 Bridge: Information for Pharmacies
• CMS — Medicare GLP-1 Bridge: Information for Providers
• CMS — Medicare GLP-1 Bridge program overview
• CMS — Pharmacy NCPDP Reject Code Troubleshooting Reference Tool, June 2026
• CMS — Medicare GLP-1 Bridge Expectations and FAQs for Part D Plans
• Medicare — GLP-1 Drugs for $50 a Month
• Medicare — Weight Loss Drug Coverage

FDA

• FDA — Foundayo approval
• FDA — Compounding and the FDA: Questions and Answers
• FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA — Semaglutide shortage resolution and compounding policy update
• FDA — Tirzepatide shortage-resolution decision

Manufacturer and provider pricing

• NovoCare — Wegovy pharmacy pricing
• NovoCare — Wegovy cash-program terms
• LillyDirect — Zepbound pricing
• Lilly — Foundayo coverage and savings
• Ro — Weight-loss program pricing
• Ro — Government-insurance policy
• Ro — GLP-1 Insurance Coverage Checker
• Ro — Terms of Use
• Sesame — Online weight-loss program
• Aetna — Medicare GLP-1 Bridge coverage overview

Pharmacy operations and voice of customer

• Pharmacy Times — Medicare's New GLP-1 Bridge Program: What Pharmacists Need to Know Before Dispensing
• Drug Topics — FAQ: The Medicare GLP-1 Bridge—What Independent Pharmacists Need to Know
• Medicare Rights Center — GLP-1 Weight-Loss Drug Demonstration Begins July 2026
• r/medicare — Has anyone qualified for the new Medicare GLP-1 Bridge program?
• r/pharmacy — Medicare Bridge program GLP-1 billing

Advertising disclosure: Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We may earn commission from some commercial services linked after the Bridge troubleshooting and eligibility sections. That compensation does not affect our billing instructions, reject-code guidance, or the order in which we present government-program options.